Then, in order to verify the ability of these alterations in LX2 cells to promote HCC development and progression, we used the IL-17a and FAP overexpression cell lines (IL-17-OE and FAP-OE) and their negative control cell lines (IL-17-NC and FAP-NC) with the HCC cell line SNU387 at an LX2 cell: SNU387 cell ratio of 1:5 to carry out the subcutaneous tumorigenesis assay in mice. The gene discussed is IL17A; the disease is hepatocellular carcinoma.